MCM
LXRX icon

Manchester Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Manchester Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,380
Closed -$1.76K – 1189
2024
Q4 		$1.76K Hold
2,380
– – ﹤0.01% 1001
2024
Q3 		$3.74K Hold
2,380
– – ﹤0.01% 927
2024
Q2 		$4K Buy
+2,380
New +$4.27K ﹤0.01% 872

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Manchester Capital Management's LXRX Position: Q1 2025 in Review

Manchester Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 2,380 shares — an estimated $1.76K sold.

Manchester Capital Management first reported a position in LXRX in Q2 2024 and held it in 3 quarters. The position peaked at $4K in Q2 2024. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.

  • Manchester Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Manchester Capital Management sold 2,380 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $1.76K.
  • Manchester Capital Management first reported a position in Lexicon Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Manchester Capital Management's Lexicon Pharmaceuticals position peaked at $4K in Q2 2024.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.

Based on Manchester Capital Management's 13F filing for Q1 2025, filed 9 May 2025.